Angiotensin-(1–7) Administration Reduces Oxidative Stress in Diabetic Bone Marrow
- 20 March 2012
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 153 (5), 2189-2197
- https://doi.org/10.1210/en.2011-2031
Abstract
Diabetics have an increased risk of developing cardiovascular disease, in part due to oxidative stress, resulting in endothelial nitric oxide synthase (eNOS) dysfunction. Studies have demonstrated that angiotensin-(1–7) [Ang-(1–7)] can activate eNOS activity. Because the bone marrow is a primary source of a number of progenitors important in physiological homeostasis and healing, the goal of this study was to evaluate the in vivo effects of Ang-(1–7) treatment on oxidative stress and the ensuing nitrative stress in diabetic bone marrow and its potential pathways. BKS.Cg-Dock7m +/+ Leprdb/J mice and their heterozygous controls were administered Ang-(1–7) alone or combined with A-779, losartan, PD123,319, nitro-l-arginine methyl ester, or icatibant sc for 14 d. The bone marrow was then collected to measure nitric oxide levels, eNOS phosphorylation, and expression of nitric oxide synthase, superoxide dismutase, and p22-phox. Nitric oxide levels in the bone marrow were significantly decreased in diabetic mice, and Ang-(1–7) treatment was able to significantly increase these measures (P < 0.01). This effect was blocked by the coadministration of PD123,319, A-779, nitro-l-arginine methyl ester, and icatibant. In addition, Ang-(1–7) treatment reversed the paradoxical increase in eNOS and neuronal nitric oxide synthase expression and decreased the phosphorylation of eNOS at Thr495 seen in diabetic mice. Ang-(1–7) also reversed diabetes-induced production of reactive oxygen species by decreasing p22-phox expression and increasing superoxide dismutase 3 expression, leading to a significant reduction in 3-nitrotyrosine formation in diabetic bone marrow (P < 0.05). Our findings demonstrate that Ang-(1–7) administration decreases diabetes-induced oxidative stress in the bone marrow and modifies pathways involved in eNOS dysfunction.Keywords
This publication has 45 references indexed in Scilit:
- Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker ratsAmerican Journal of Physiology-Renal Physiology, 2011
- Angiotensin-(1–7) upregulates cardiac nitric oxide synthase in spontaneously hypertensive ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Angiotensin-(1-7) stimulates the phosphorylation of Akt in rat extracardiac tissues in vivo via receptor MasRegulatory Peptides, 2010
- Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancerCancer Chemotherapy and Pharmacology, 2005
- Effect of insulin nitration by peroxynitrite on its biological activityBiochemical and Biophysical Research Communications, 2005
- Protein Tyrosine Nitration in the Mitochondria from Diabetic Mouse HeartPublished by Elsevier BV ,2003
- The kallikrein-kinin and the renin-angiotensin systems have a multilayered interactionAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2003
- Effect of angiotensin II and angiotensin(1–7) on hematopoietic recovery after intravenous chemotherapyCancer Chemotherapy and Pharmacology, 2003
- Diabetes, oxidative stress, and antioxidants: A reviewJournal of Biochemical and Molecular Toxicology, 2003
- Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.1995